The effect of tumor size and lymph node status on breast carcinoma lethality
Open Access
- 15 October 2003
- Vol. 98 (10), 2133-2143
- https://doi.org/10.1002/cncr.11765
Abstract
BACKGROUND It has long been known that both tumor size and the presence of malignant disease in the regional lymph nodes are indicators of outcome for patients with invasive breast carcinoma; however, the way in which these two characteristics could be integrated into an overall assessment of prognosis has not been obvious. METHODS Kaplan–Meier survival estimates (15 years) according to tumor size and lymph node status were obtained for women with invasive breast carcinoma who were observed at the University of Southern California/Van Nuys Breast Center (Van Nuys, California) or at Massachusetts General Hospital (Boston, Massachusetts). RESULTS To isolate the individual contributions to death made by tumor size and lymph node status, data were sorted according to both of these variables. For women with tumors of equivalent size, lethality increased with increasing number of positive lymph nodes, such that there was an extra ≈6% chance of death associated with each positive lymph node. For women with equivalent lymph node status, tumor size was associated with increased lethality, such that each millimeter of tumor diameter was associated with an additional ≈1% chance of death. The overall lethality was equal to the sum of the contribution from lymph node status and the contribution from tumor size, and this finding led to the creation of a new technique (the Size+Nodes method) for predicting outcome. CONCLUSIONS The Size+Nodes method was shown to be capable of accurately estimating the risk of death due to invasive breast carcinoma from information on the size of the primary tumor and the number of positive lymph nodes. In addition, this method was used to stratify women into groups according to breast carcinoma lethality. In contrast, classification of women according to lymph node positivity, T status, or disease stage created groups with wide and overlapping levels of lethality. Cancer 2003. © 2003 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Predicting the survival of patients with breast carcinoma using tumor sizeCancer, 2002
- Approaches to Breast-Cancer StagingNew England Journal of Medicine, 2000
- Role of immunohistochemical detection of lymph-node metastases in management of breast cancerThe Lancet, 1999
- Dormancy of Mammary Carcinoma After MastectomyJNCI Journal of the National Cancer Institute, 1999
- Molecular prognostic markers in breast cancerBreast Cancer Research and Treatment, 1998
- Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes.Journal of Clinical Oncology, 1996
- Oncogene Products and Other Diagnostic Markers in Human Breast Cancer Patients.Annals of the New York Academy of Sciences, 1996
- Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.Journal of Clinical Oncology, 1993
- Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study.Journal of Clinical Oncology, 1991